Mizuho analyst Bradley Bowers initiated coverage of Tempus AI (TEM) with an Outperform rating and $100 price target Tempus is a leader player in precision oncology diagnostics and AI-enabled healthcare data services, the analyst tells investors in a research note. The firm views the company’s core market of precision oncology diagnostics as among the most attractive in healthcare with a $40B total addressable market that is growing at 30% annually. It sees Tempus AI’s products driving at or above-market growth over the next few years, which it says is discounted at current share levels.
Claim 55% Off TipRanks
New trading tool for TEM bullsPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Here’s Why Tempus AI Stock (TEM) Is Rallying Today
- AI Daily: Pentagon close to designating Anthropic ‘supply chain risk’
- Dollar General downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls
- Tempus AI initiated with an Outperform at Baird
- Cathie Wood Goes Bargain Hunting on These Beaten-Down Tech Stocks